PARP inhibitors may have efficacy in selected TNBC patients outside of germline BRCA
 

The investigational PARP inhibitor talazoparib caused regression of patient-derived xenografts (PDXs) of triple-negative breast cancers (TNBC) that had BRCA mutations and also those that did not have BRCA mutations but had other alterations in DNA damage-repair pathways.

More...